Overall, the controversial evidence regarding the involvement of NLRP6 and its microbiota‐derived metabolites as regulators of gut homeostasis, as well as the different roles of NLRP3 against colitis, which possibly lays in different cell types and grades of inflammasome activation, indicates the need for further research in human disease settings and into the downstream mechanisms that control these effects. The gene discussed is NLRP6; the disease is colitis.